Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare Biotechnology
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc > Novak ...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Post by MrMugsyon Sep 29, 2021 4:41pm
275 Views
Post# 33938591

Novak ...

Novak ...Raymond James analyst David Novak is firmly behind Knight Therapeutics, giving the company an “Outperform 2” rating in an update to clients on September 24.
...

Looking at the announced deal, Novak wrote in his report, “While not immediately accretive to Knight, the transaction is a return to form for Knight, doing what it does best: leveraging its infrastructure to in-license therapeutics for underserved jurisdictions, with significant forward-looking revenue potential, while putting minimal shareholder capital at risk.”
...

Novak projects continued modest growth for the company from a financial standpoint, forecasting revenue of $243 million in 2021 for a potential year-over-year increase of 21.5 per cent, followed by another jump to a projected $289 million for 2022, marking a potential year-over-year increase of 18.9 per cent.

https://www.cantechletter.com/2021/09/knight-therapeutics-strengthens-its-portfolio-raymond-james-says/
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities